Reduced prefrontal activation during working and long-term memory tasks and impaired patient-reported cognition among cancer survivors postchemotherapy compared with healthy controls
- PMID: 26484435
- PMCID: PMC4707984
- DOI: 10.1002/cncr.29737
Reduced prefrontal activation during working and long-term memory tasks and impaired patient-reported cognition among cancer survivors postchemotherapy compared with healthy controls
Abstract
Background: Patients who receive adjuvant chemotherapy have reported cognitive impairments that may last for years after the completion of treatment. Working memory-related and long-term memory-related changes in this population are not well understood. The objective of this study was to demonstrate that cancer-related cognitive impairments are associated with the under recruitment of brain regions involved in working and recognition memory compared with controls.
Methods: Oncology patients (n = 15) who were receiving adjuvant chemotherapy and had evidence of cognitive impairment according to neuropsychological testing and self-report and a group of age-matched, education group-matched, cognitively normal control participants (n = 14) underwent functional magnetic resonance imaging. During functional magnetic resonance imaging, participants performed a nonverbal n-back working memory task and a visual recognition task.
Results: On the working memory task, when 1-back and 2-back data were averaged and contrasted with 0-back data, significantly reduced activation was observed in the right dorsolateral prefrontal cortex for oncology patients versus controls. On the recognition task, oncology patients displayed decreased activity of the left-middle hippocampus compared with controls. Neuroimaging results were not associated with patient-reported cognition.
Conclusions: Decreased recruitment of brain regions associated with the encoding of working memory and recognition memory was observed in the oncology patients compared with the control group. These results suggest that there is a reduction in neural functioning postchemotherapy and corroborate patient-reported cognitive difficulties after cancer treatment, although a direct association was not observed. Cancer 2016;122:258-268. © 2015 American Cancer Society.
Keywords: cancer-related cognitive impairment (CRCI); functional magnetic resonance imaging (fMRI); patient-reported outcomes (PRO); recognition memory; working memory.
© 2015 American Cancer Society.
Figures




Similar articles
-
The Working Memory and Dorsolateral Prefrontal-Hippocampal Functional Connectivity Changes in Long-Term Survival Breast Cancer Patients Treated with Tamoxifen.Int J Neuropsychopharmacol. 2017 May 1;20(5):374-382. doi: 10.1093/ijnp/pyx008. Int J Neuropsychopharmacol. 2017. PMID: 28177081 Free PMC article.
-
Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer.Hum Brain Mapp. 2011 Aug;32(8):1206-19. doi: 10.1002/hbm.21102. Epub 2010 Jul 28. Hum Brain Mapp. 2011. PMID: 20669165 Free PMC article.
-
Towards a biomarker model for cognitive improvement: No change in memory-related prefrontal engagement following a negative cognitive remediation trial in bipolar disorder.J Psychopharmacol. 2018 Oct;32(10):1075-1085. doi: 10.1177/0269881118783334. Epub 2018 Jul 4. J Psychopharmacol. 2018. PMID: 29969938 Clinical Trial.
-
Cancer 'survivor-care': II. Disruption of prefrontal brain activation top-down control of working memory capacity as possible mechanism for chemo-fog/brain (chemotherapy-associated cognitive impairment).J Clin Pharm Ther. 2013 Aug;38(4):265-8. doi: 10.1111/jcpt.12071. Epub 2013 May 8. J Clin Pharm Ther. 2013. PMID: 23656522 Free PMC article. Review.
-
Functional MRI studies in non-CNS cancers.Brain Imaging Behav. 2013 Dec;7(4):388-408. doi: 10.1007/s11682-013-9249-9. Brain Imaging Behav. 2013. PMID: 23934234 Review.
Cited by
-
Four decades of chemotherapy-induced cognitive dysfunction: comprehensive review of clinical, animal and in vitro studies, and insights of key initiating events.Arch Toxicol. 2022 Jan;96(1):11-78. doi: 10.1007/s00204-021-03171-4. Epub 2021 Nov 2. Arch Toxicol. 2022. PMID: 34725718 Review.
-
Doxorubicin-Induced Cognitive Impairment: The Mechanistic Insights.Front Oncol. 2021 May 13;11:673340. doi: 10.3389/fonc.2021.673340. eCollection 2021. Front Oncol. 2021. PMID: 34055643 Free PMC article. Review.
-
Seeing through "brain fog": neuroimaging assessment and imaging biomarkers for cancer-related cognitive impairments.Cancer Imaging. 2024 Nov 18;24(1):158. doi: 10.1186/s40644-024-00797-2. Cancer Imaging. 2024. PMID: 39558401 Free PMC article. Review.
-
Evaluation of a Novel Synthetic Peptide Derived from Cytolytic Mycotoxin Candidalysin.Toxins (Basel). 2022 Oct 11;14(10):696. doi: 10.3390/toxins14100696. Toxins (Basel). 2022. PMID: 36287965 Free PMC article.
-
Detecting microstructural alterations of cerebral white matter associated with breast cancer and chemotherapy revealed by generalized q-sampling MRI.Front Psychiatry. 2023 Jun 9;14:1161246. doi: 10.3389/fpsyt.2023.1161246. eCollection 2023. Front Psychiatry. 2023. PMID: 37363171 Free PMC article.
References
-
- Vardy J, Wefel JS, Ahles T, Tannock IF, Schagen SB. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol. 2008;19:623–629. - PubMed
-
- Nelson CJ, Nandy N, Roth AJ. Chemotherapy and cognitive deficits: mechanisms, findings, and potential interventions. Palliat Support Care. 2007;5:273–280. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical